Blog

We were recently asked by one of our customers if our products could serve as a platform to develop companion diagnostics during drug testing. Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post-marketing.

Traditional tests for immunologic diseases measure disease activity with non-specific injury markers, markers of fully evolved injury, or by measuring the disease agent itself. A need exists to predict whether immunological disease will occur with tests which are highly specific for that disease.